Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

NCT00000630 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIVAC-1e
BIOLOGICAL: gp160 Vaccine (MicroGeneSys)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)